天圣制药集团股份有限公司 2024 年度独立董事述职报告 独立董事 杨大坚 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，自任职以来，严格按照《公司法》《证券法》《上市公司独立董事管 理办法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》《公司章程》及《独立董事工作制度》 等相关法律法规及规章指引的规定和要求，诚信、勤勉、独立地履行独立董事职 责，积极出席相关会议，维护公司利益和股东合法权益，对公司规范、稳定、健 康地发展起到了积极的推动作用。现将本人在 2024 年度的工作情况向各位股东 及股东代表进行汇报。 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 杨大坚，1960 年 2 月出生，中国国籍，无境外居留权，香港理工大学药物 化学专业博士，重庆市中药研究院首席科学家。曾获国务院特殊贡献专家奖、编 著出版了《名贵中药材鉴别》。曾任重庆市中药研究院副研究员，香港理工大学 中药研究总监，及重庆市中药研究院院长，并曾于 2013 年 12 月至 2015 年 1 月 担任天圣制药集团 ...

天圣制药集团股份有限公司 2024 年度独立董事述职报告 本人已向公司递交了独立性自查情况表，按照监管规则进行了独立性自查。 报告期内，本人具备中国证监会《上市公司独立董事管理办法》所要求的独立性， 不存在影响独立性的情况。 二、独立董事年度履职情况 （一）出席董事会、股东大会会议情况 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》及《独立董事工作制度》等相关法 律及规章指引的规定和要求，诚信、勤勉、独立地履行独立董事职责，积极出席 相关会议，维护公司利益和股东合法权益，对公司规范、稳定、健康地发展起到 了积极的推动作用。现将本人在 2024 年度本人工作情况向各位股东及股东代表 进行汇报。 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 易润忠，1971 年 8 月出生，中国国籍，无境外永久居留权，重庆大学机电 控制及自动化硕士学位，正高级工程师，重庆科技学院教授、 ...

（一）个人工作履历、专业背景以及兼职情况 李定清，1963 年 5 月出生，中国国籍，无境外居留权，西南大学经济管理 专业硕士，重庆工商大学会计学院教授、硕士研究生导师。曾获重庆市教学成果 一等奖 2 项、重庆市高等教育质量工程 2 项（项目负责人）、获重庆工商大学 首届"教学名师"称号，2013 年《会计学原理》（课程负责人）获重庆市精品 资源共享课程，2022 年获重庆市教学成果特等奖 1 项。曾任重庆商学院财务处 副处长、校办产业处副处长、财务会计系副主任，重庆工商大学应用技术学院院 长、会计学院院长。现任重庆市建设会计学会副会长，现任重庆市泓禧科技股份 有限公司、四川银钢一通凸轮科技股份有限公司、天圣制药集团股份有限公司独 立董事。 报告期内在董事会专门委员会任职情况：任审计委员会主任委员、提名委员 会委员、薪酬与考核委员会委员、战略委员会委员。 （二）独立性情况说明 2024 年度独立董事述职报告 独立董事 李定清 各位股东及股东代表： 本人作为天圣制药集团股份有限公司（以下简称"天圣制药"、"公司"） 独立董事，自任职以来，严格按照《公司法》《证券法》《上市公司独立董事管 理办法》《深圳证券交易所 ...

Financial Performance - The company's revenue for Q1 2025 was ¥115,533,088.70, a decrease of 21.93% compared to ¥147,987,552.62 in the same period last year[5] - The net loss attributable to shareholders was ¥12,416,708.34, an improvement of 39.32% from a loss of ¥20,461,696.10 in the previous year[5] - Net profit for the period was a loss of ¥12,537,029.71, compared to a loss of ¥20,731,689.79 in the previous period, showing an improvement of approximately 40%[20] - The company reported a total asset of CNY 2,717,977,142.99 as of March 31, 2025, a slight decrease from CNY 2,736,124,198.16 at the beginning of the period[15] - Total operating revenue decreased to ¥115,533,088.70 from ¥147,987,552.62, a decline of approximately 22%[19] - Total operating costs reduced to ¥140,612,164.96 from ¥173,317,426.29, a decrease of about 19%[19] Cash Flow - The net cash flow from operating activities increased significantly by 831.46%, reaching ¥31,794,300.40 compared to ¥3,413,366.26 in the same period last year[5] - Cash flow from operating activities generated ¥31,794,300.40, significantly up from ¥3,413,366.26 in the previous period[21] - Cash flow from investment activities showed a net outflow of ¥5,598,162.05, an improvement from a net outflow of ¥12,308,817.04 in the previous period[21] - Net cash flow from financing activities was $1,431,099.46, a significant decrease from $106,889,610.07 in the previous period[22] - Cash inflows from financing activities totaled $93,300,000.00, down from $167,000,000.00 year-over-year[22] - Cash outflows for debt repayment amounted to $87,850,000.00, an increase from $56,100,000.00 in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,717,977,142.99, a slight decrease of 0.66% from ¥2,736,124,198.16 at the end of the previous year[5] - Current assets totaled CNY 705,046,116.30, showing a marginal increase from CNY 702,436,533.60[15] - The total liabilities decreased slightly to CNY 716,326,000.35 from CNY 721,802,602.07, reflecting a reduction of about 0.8%[16] - The company's equity remained stable at CNY 1,400,779,329.86, unchanged from the previous period[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,396, with the largest shareholder holding 32.89% of the shares[10] - The company's weighted average return on equity was -0.62%, an improvement from -0.98% in the previous year[5] Research and Development - Research and development expenses rose by 42% year-on-year, driven by the advancement of new projects and drug re-registration[11] - Research and development expenses increased to ¥8,201,323.83 from ¥5,779,375.24, representing a rise of about 42%[19] Regulatory and Compliance - The company has not received any conclusive opinions or decisions from the China Securities Regulatory Commission regarding the ongoing investigation[14] - The company will actively cooperate with the regulatory body during the investigation period[14] - The company has not audited its first-quarter report for 2025[23] - The new accounting standards will be implemented starting in 2025[23] Other Financial Metrics - The company reported a decrease in accounts receivable from CNY 120,099,455.35 to CNY 94,754,796.53, a decline of approximately 21.1%[15] - The company’s inventory decreased from CNY 106,799,072.77 to CNY 100,225,778.99, a reduction of about 6.2%[15] - The company recorded a 244% increase in other income, primarily from a significant VAT refund received this period[11] - The company reported a decrease in sales expenses to ¥39,291,462.43 from ¥49,164,808.86, a reduction of approximately 20%[19] - The company recorded an investment loss of ¥558,811.98, contrasting with a gain of ¥35,587.88 in the previous period[19] - The basic and diluted earnings per share improved to -0.0390 from -0.0643, indicating a reduction in loss per share[20] - Cash and cash equivalents increased to CNY 294,493,873.46 from CNY 270,419,234.88, representing an increase of approximately 8.0%[15] - Short-term borrowings rose significantly to CNY 115,109,694.44 from CNY 80,080,055.56, indicating a 43.7% increase[16] - Other cash outflows related to financing activities were $425,000.00, down from $1,161,083.39 year-over-year[22]

Financial Performance - The company's operating revenue for 2024 was approximately ¥569.71 million, a decrease of 1.66% compared to ¥579.33 million in 2023[19]. - The net profit attributable to shareholders for 2024 was approximately -¥87.40 million, showing an improvement of 6.09% from -¥93.07 million in 2023[19]. - The cash flow from operating activities for 2024 was approximately ¥50.15 million, a significant increase of 304.17% compared to -¥24.56 million in 2023[19]. - The total assets at the end of 2024 were approximately ¥2.74 billion, a decrease of 2.66% from ¥2.81 billion at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.01 billion, down 4.10% from ¥2.09 billion at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.2749, an improvement of 6.08% from -¥0.2927 in 2023[19]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, amounting to approximately -¥109.53 million in 2024, a decline of 6.24% from -¥103.10 million in 2023[19]. - The weighted average return on net assets for 2024 was -4.27%, slightly improved from -4.36% in 2023[19]. Revenue Breakdown - The company's total revenue for Q1 was approximately 148 million, Q2 was about 133 million, Q3 was around 121 million, and Q4 reached approximately 167 million[23]. - The revenue from self-manufactured oral solid preparations increased by 11.49% to ¥256,633,167.71, accounting for 45.05% of total revenue[61]. - The revenue from self-manufactured small volume injections decreased by 24.40% to ¥143,397,102.67, accounting for 25.17% of total revenue[61]. Cash Flow and Investments - Net cash flow from operating activities improved significantly to ¥50,146,536.51 in 2024, compared to a negative cash flow of ¥24,561,754.07 in 2023, an increase of 304.17%[77]. - Cash flow from investing activities showed a net inflow of ¥5,568,663.15 in 2024, a turnaround from a net outflow of ¥82,080,011.17 in 2023, an increase of 106.78%[77]. - Cash flow from financing activities increased significantly to ¥50,557,204.74 in 2024, compared to a negative cash flow of ¥11,203,509.75 in 2023, an increase of 551.26%[77]. - Total cash and cash equivalents increased by ¥106,272,404.40 in 2024, reversing a decrease of ¥117,845,274.99 in 2023, a change of 190.18%[77]. Research and Development - The company has established a specialized research platform for improved new drug development, enhancing its capabilities in traditional Chinese medicine and chemical drugs[38]. - The research and development model includes both independent and collaborative approaches, with partnerships established with several universities and research institutions[38]. - The company is currently developing several new products, including sodium bicarbonate injection and vitamin B6 injection, aimed at expanding its product line[74]. - R&D investment decreased to ¥22,752,050.49 in 2024 from ¥30,916,051.19 in 2023, a decline of 26.41%[75]. - R&D expenditure as a percentage of operating revenue fell to 3.99% in 2024 from 5.34% in 2023, a decrease of 1.35%[75]. Production and Quality Control - The company emphasizes quality control in production, adhering to national drug management laws and regulations[41]. - The company has implemented a comprehensive quality management system, ensuring all materials undergo strict quality inspections before production[43]. - The company has a strong focus on quality management, with Mr. Jiang Changhong serving as the Quality Management Department Head[141]. - The company has established a robust management team with a mix of academic and practical experience in the pharmaceutical industry[139]. Market and Strategic Initiatives - The company is focused on modernizing its pharmaceutical operations, integrating drug research, production, and sales[33]. - The company plans to enhance its marketing efforts and develop the "Tian Sheng Cloud" APP for internet pharmaceutical sales[57]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the pharmaceutical industry[101]. - The company plans to launch its own internet pharmaceutical sales platform by 2025, leveraging AI tools to enhance sales and brand influence[45]. Governance and Compliance - The company maintained strict compliance with relevant laws and regulations, ensuring effective corporate governance and protecting investor interests[126]. - The company has established a market value management system and approved a valuation enhancement plan to improve its market standing[123]. - The company has a dedicated financial department that operates independently, ensuring sound financial management and decision-making[131]. - The company has established a robust internal audit system to enhance risk control and internal supervision[129]. Environmental Responsibility - The company has invested a total of 1.9336 million yuan in environmental protection during the reporting period, including 0.4992 million yuan for operation and maintenance of environmental facilities and 1.3353 million yuan for upgrading the wastewater treatment station[176]. - The company has implemented the "Three Simultaneities" principle for all construction projects, ensuring compliance with environmental impact assessments[168]. - The company has established an emergency response plan for environmental incidents, which has been reviewed by experts and aims to minimize environmental risks from accidents[175]. - The company has successfully managed its wastewater discharge, with all monitored pollutants reported as not exceeding the standards[170]. Social Responsibility - The company emphasizes its commitment to social responsibility, focusing on economic benefits while protecting the rights of stakeholders and participating in public welfare[178]. - The company provides monthly financial assistance of 1,000 yuan to a sick child in Chongqing, reducing the family's burden until the child graduates from university[182]. - The company has established a strategic partnership with local communities to promote rural revitalization through the development of traditional Chinese medicine resources[183]. Risk Management - The company recognizes R&D risks, including potential misalignment with market needs and regulatory challenges, and is focused on optimizing its R&D processes[117]. - The pharmaceutical industry faces significant policy risks, including stricter regulations and cost control measures, which could impact future development[115]. - The company is addressing drug price risks due to policy-driven price reductions and market competition by enhancing cost control and marketing strategies[119]. Shareholder Engagement - The company emphasizes the protection of shareholder rights, ensuring equal treatment for all shareholders, especially minority shareholders, during significant decision-making processes[179]. - The company actively engages with investors through various channels, including an investor hotline and performance briefings, to ensure transparent communication[179]. - The company held its annual general meeting on May 16, 2024, with a participation rate of 6.45% from investors[133].

证券代码：002872 证券简称：ST 天圣 公告编号：2025-017 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易自 2019 年 6 月 5 日起被实施其他 风险警示。具体内容详见公司在指定信息披露媒体上刊登的《关于公司股票交 易被实行其他风险警示的公告》、《关于公司股票交易被实行其他风险警示相 关事项的进展公告》。 二、关于争取撤销其他风险警示所采取的措施及有关工作进展情况 1、公司进一步加强了董事、监事、高级管理人员及广大业务人员对相关法 律、法规、 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-016 天圣制药集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、基本情况 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召 开的第六届董事会第十次会议，以及 2025 年 3 月 10 日召开的 2025 年第一次 临时股东大会，审议通过了《关于修订<公司章程>的议案》，具体内容详见公 司 分 别 于 2025 年 2 月 22 日 、2025 年 3 月 11 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的相关公告。 二、工商变更登记情况 近日，公司已完成了工商变更登记及《公司章程》备案手续，取得了重庆 市市场监督管理局换发的《营业执照》，公司本次《营业执照》的变更仅涉及 经营范围变更，其他事项不变，变更后的《营业执照》相关信息如下： 1、名称：天圣制药集团股份有限公司 8、经营范围：许可项目：药品生产；药品零售；药品进出口；药品委托 生产；药品批发；药品互联网信息服务； ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-015 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易自 2019 年 6 月 5 日起被实施其他 风险警示。具体内容详见公司在指定信息披露媒体上刊登的《关于公司股票交 易被实行其他风险警示的公告》、《关于公司股票交易被实行其他风险警示相 关事项的进展公告》。 二、关于争取撤销其他风险警示所采取的措施及有关工作进展情况 1、公司进一步加强了董事、监事、高级管理人员及广大业务人员 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-014 （2）网络投票时间：其中，通过深圳证券交易所交易系统进行网络投票的 具体时间为：2025 年 3 月 10 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2025 年 3 月 10 日 9:15 至 15:00 期间的任意时间。 2、现场会议召开地点：重庆市渝北区创新经济走廊食品城西一街天圣制药 集团股份有限公司七楼会议室。 天圣制药集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会决议的情形。 一、会议召开的基本情况 1、会议召开时间 （1）现场会议时间：2025 年 3 月 10 日（星期一）下午 14:00 开始。 3、会议召集人：天圣制药集团股份有限公司（以下简称"公司"）第六届 董事会。 4、现场会议主持人：董事长刘爽先生。 5、会议召开方式：现场记名投票 ...

地址：北京市朝阳区光华路正大中心北塔 11-12 层 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天圣制药集团股份有限公司 2025 年第一次临时股东大会之 法律意见书 二〇二五年三月 法律意见书 北京中银律师事务所 关于天圣制药集团股份有限公司 2025 年第一次临时股东大会之 法律意见书 致：天圣制药集团股份有限公司 北京中银律师事务所（以下简称"本所"）接受天圣制药集团股份有限公司 （以下简称"公司"）的委托，指派见证律师出席公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）、 《上市公司治理准则》（以下简称"《治理准则》"）等法律、法规和规范性文 件以及《天圣制药集团股份有限公司章程》（以下简称"《公司章程》"）的规 定就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序、表 决结果等有关事宜出具法律意见书。 本所律师依据法律 ...